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Abstract: There are differences in the incidence, clinical presentation, molecular pathogenesis,
and outcome of colorectal cancer (CRC) based on tumor location. Emerging research suggests that the
perioperative carcinoembryonic antigen (CEA) ratio (post-op/pre-op CEA) is a prognostic factor for
CRC patients. We aimed to determine the association between CEA ratio, tumor location, and overall
survival (OS) among patients with CRC. We analyzed 427 patients who underwent resection for CRC
at the University of Kansas Medical Center. After excluding those without pre- or post-operative CEA
data, 207 patients were classified as either high (≥0.5) or low (<0.5) ratio. Primary outcomes were as
follows: (1) OS stratified by CEA ratio; (2) OS stratified by tumor location; (3) OS stratified by tumor
location among those with CEA elevation > 5 ng/mL at the time of recurrence. The Kaplan–Meier
method was used to estimate survival rates. The median age was 62 years (inter-quartile range 51–71),
55% were male, 41% were smokers, 71% had left-sided tumors, the median pre-operative CEA was 3.1
ng/mL (inter-quartile range (IQR) 1.5–9.7), and 57% had a CEA ratio ≥0.5. The OS rates were 65.1%
and 86.3% in patients with high versus low CEA ratios, respectively (log-rank p-value = 0.045). The OS
rates were 64.4% and 77.3% in patients with right-sided vs. left-sided tumors, respectively (log-rank
p-value = 0.5). Among patients with CEA levels greater than 5 at the time of recurrence, the OS
rates were 42.9% and 43.4% in patients with right-sided vs. left-sided tumors, respectively (log-rank
p-value = 0.7). There was a significantly higher survival among patients with low CEA ratios than
among those with high CEA ratios. There was no difference in OS between left- versus right-sided
tumors. Among patients with CEA elevation > 5 ng/mL at the time of recurrence, there was no
difference in OS between left versus right-sided tumors. These findings warrant validation in a larger
cohort as our sample size was limited.
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1. Introduction
The outcomes of patients with colorectal cancer (CRC) differ based on tumor location [1].
For example, overall survival among patients who undergo curative resection for CRC differs according
J. Clin. Med. 2020, 9, 3848; doi:10.3390/jcm9123848 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 3848 2 of 6
to the location of the tumor [2]. A recent systematic review found that left-sided colon cancer is associated
with improved survival [3], suggesting that tumor sidedness could be an important prognostic factor.
While postoperative serum carcinoembryonic antigen (CEA) level is routinely used as a marker for
possible metastatic disease, the perioperative CEA ratio (post-op/pre-op CEA) may be an important
emerging prognostic factor for CRC patients [4,5] and may be especially important in patients with
high preoperative CEA levels [6]. To our knowledge, the association between perioperative CEA
ratio and tumor location has not been previously established. We aimed to determine the association
between CEA ratio, tumor location, and overall survival (OS) among patients with CRC.
2. Experimental Section
We conducted a retrospective cohort analysis of the effect of perioperative CEA ratio and the
location of primary colorectal cancer on overall survival. Study subjects included all patients diagnosed
with stage II and III biopsy-proven colorectal adenocarcinoma at the University of Kansas Medical
Center (KUMC) between February 2008 and March 2018, who had their CEA levels checked during the
course of treatment and follow up and who underwent definitive surgical resection with or without
adjuvant chemotherapy and/or radiation. Study subjects had at least two years of follow up unless
recurrence occurred earlier. Patients with other actively treated malignancies diagnosed in the last five
years were excluded, except those with basal cell carcinoma of the skin, carcinoma in situ of the cervix,
and ductal carcinoma in-situ of the breast.
Participant demographics, self-reported history of cigarette smoking, clinicopathological
characteristics, and tumor recurrence information were collected using REDCap, a secure web-based
electronic data capture software hosted at KUMC [7,8]. Patients who died of any other non-CRC cause
that occurred before clinical recurrence of CRC were censored at the time of death.
We analyzed records of 427 patients with CRC who underwent resection at the University of
Kansas Cancer Center between February 2008 and March 2018. CEA tests were obtained by standard
electrochemiluminescence immunoassay as part of the routine care of these patients. We excluded
those who did not have data on pre- or post-operative CEA levels. We calculated the CEA ratio as
post-operative CEA levels/pre-operative CEA levels. Patients were classified as either high (≥0.5) or
low (<0.5) CEA ratio based on previously published literature [9]. Subjects were further classified
as having right-sided colon cancer if the primary tumor was located in the cecum, ascending colon,
hepatic flexure, or transverse colon; and as having left-sided colon cancer if the tumor site was within
the splenic flexure, descending colon, sigmoid colon, rectosigmoid junction, or rectum. We determined
cancer recurrence with imaging evidence of distant disease.
Primary outcomes included overall survival (OS) stratified by CEA ratio, OS stratified by tumor
location, and OS stratified by tumor location among those with CEA elevation >5 ng/mL at the time of
recurrence. Overall survival was measured from the time of surgical resection to the time of death due to any
cause. We used the Kaplan–Meier method to estimate survival rates. Cox proportional hazards models were
used for multivariable analysis. Variables for inclusion in multivariable regression models were selected a
priori based on known or suspected risk factors for survival. All tests were two-sided with a significance
level of p < 0.05. Stata v13 was used to perform all analyses (StataCorp, College Station, TX, USA).
The retrospective study was reviewed by the University of Kansas Medical Center Human
Research Protection Program. The type of review was a Flexible Institutional Review Board review.
The study was eligible for Flexible IRB Review because it was deemed minimal risk and is not associated
with any federal funding or support.
3. Results
We analyzed a total of 207 patients with median age of 62 years (inter-quartile range of 51–71).
Of these, 55% were male, 41% were smokers, and 71% had left-sided tumors (Table 1). The median
pre-operative CEA was 3.0 ng/mL (IQR 1.5–9.7), and the median post-operative CEA was 1.7 ng/mL
(IQR 1.1–2.9). Overall, 57% had CEA ratio ≥ 0.5. (Table 1). The overall survival (OS) rates were 65.1%
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in patients with high CEA ratios and 86.3% in patients with low CEA ratios (log-rank p-value = 0.045)
(Figure 1). The OS rates were 64.4% in patients with right CRC and 77.3% in patients with left CRC
(log-rank p-value = 0.5) (Figure 2). Among patients with CEA levels greater than 5 at the time of
recurrence, the OS rates were 42.9% in patients with right CRC and 43.4% in patients with left CRC
(log-rank p-value = 0.7) (Figure 3).
When adjusted for smoking status and tumor stage, the effect of tumor location on survival was
modified by perioperative CEA level (p-value for interaction term< 0.001). In the analysis stratified
by tumor location, however, the numbers in the right-sided tumor group were too small to permit
inferential analysis. Table 2 shows the effect of tumor location on OS, adjusting for perioperative CEA
level, smoking status, and tumor stage without including an interaction term between perioperative
CEA level and tumor location.
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Left-Sided n (%) Right-Sided n (%)
Age (years), median IQR 60 (48–68) 65 (52–73) 62 (51–71)
Sex
Male 81 (82.7) 17 (17.4) 98 (55.4)
Female 45 (57.0) 34 (43.0) 79 (44.6)
Smoking
No 69 (68.3) 32 (31.7) 95 (58.6)
Yes 50 (74.6) 17 (25.3) 67 (41.4)
CEA ratio
<0.5 53 (69.7) 23 (30.3) 76 (42.7)
≥0.5 73 (71.6) 29 (28.4) 102 (57.3)
Tumor stage
Stage 2 29 (63.0) 17 (37.0) 46 (36.2)
Stage 3 62 (76.5) 19 (23.5) 81 (63.8)
Note: Total numbers may not add up to 207 due to missing categorical data.
Table 2. The effect of tumor location on overall survival (OS), adjusting for perioperative CEA level,
smoking status, and tumor stage.
Variable
Unadjusted p-Value Adjusted p-Value
HR (95% CI) HR (95% CI)
Tumor location
Right (n = 35) Ref Ref
Left (n = 88) 0.82 (0.45–1.50) 0.5 1.06 (0.28–3.96) 0.9
CEA ratio
<0.5 (n = 52) Ref Ref
≥0.5 (n = 71) 3.06 (0.97–9.60) 0.06 1.59 (0.45–5.34) 0.5
Smoking status No (n = 79) Ref Ref
Yes (n = 44) 1.66 (0.95–2.91) 0.08 3.16 (0.97–10.32) 0.06
Tumor stage Stage 2 (n = 43) Ref Ref
Stage 3 (n = 80) 1.61 (0.75–3.42) 0.2 1.46 (0.42–5.17) 0.6
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4. Discussion
In this study, we found that there was a significantly higher OS among patients with low
perioperative CEA ratios compared to those with high perioperative CEA ratios. This finding lends
support to the potential use of perioperative CEA levels as a prognostic factor for CRC patients [4,5].
Konishi et al. suggested that preoperative CEA levels may not provide useful information in the
setting of normal post-operative CEA levels [4]. However, our results suggest that any level of
post-operative CEA can be informative for prognosis if it is paired with pre-operative CEA levels
as a ratio. The differing survival rates between patients with high versus low perioperative CEA
ratios could potentially be a marker for how to allocate resources for surveillance. Patients with
high perioperative ratios could potentially benefit from less frequent or less intense surveillance for
recurrent disease, and those with low ratios may benefit from more frequent or more intense follow up.
To confirm this, studies with longer follow up of these patients would be needed.
In secondary analyses, we also found that there was no difference in OS between left-sided
CRC and right-sided CRC in our cohort. Specifically, there was no difference in OS between left-
versus right-sided tumors among patients with post-operative CEA level > 5 at the time of recurrence.
However, we found that the effect of tumor location on survival is modified by perioperative CEA
levels, although our small sample size did not permit analyses stratified by CEA levels. This study
is among the few to evaluate the association between perioperative CEA ratio and tumor location.
While primary tumor location has important prognostic value for advanced colorectal cancer [10],
our findings suggest that prognostic models that incorporate tumor sidedness may be enhanced further
by inclusion of CEA ratio levels.
Our study was strengthened by having all the data from a single center with long and consistent
follow up for the patients. This also ensured that CEA assays were all standardized and from the
same lab, thus eliminating inter-lab discrepancies. We recognize the limitations of our study. First, the
study did not have sufficient power to detect differences in survival among patients stratified by
tumor location and CEA ratio. Such an analysis could potentially add precision to prognostic models
for advanced colon cancer by taking into account both primary tumor location and perioperative
CEA levels. The findings reported here, therefore, warrant validation in a larger cohort due to our
limited sample size. Second, many potential study participants did not have their pre-operative or
post-operative CEA levels measured. Therefore, our findings may reflect a biased sample that is not
truly representative of target patients. Finally, the interpretation of our findings is limited by losses to
follow up over time. Our survival analysis methods, however, account for losses to follow up and
reduce bias by censoring patients at their last visit.
5. Conclusions
In conclusion, this study suggests that the perioperative CEA ratio may be an important emerging
prognostic factor for CRC patients, and may exceed the current use of only post-operative CEA levels
for prognostication. Patients may benefit from individualized follow up surveillance informed by
perioperative CEA levels.
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